Rhythm Pharmaceuticals Stock Alpha and Beta Analysis
| RYTM Stock | USD 98.47 4.40 4.28% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rhythm Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rhythm Pharmaceuticals over a specified time horizon. Remember, high Rhythm Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rhythm Pharmaceuticals' market risk premium analysis include:
Beta 0.93 | Alpha (0.05) | Risk 3.22 | Sharpe Ratio 0.0107 | Expected Return 0.0343 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Rhythm Pharmaceuticals Analysis, Rhythm Pharmaceuticals Valuation, Rhythm Pharmaceuticals Correlation, Rhythm Pharmaceuticals Hype Analysis, Rhythm Pharmaceuticals Volatility, Rhythm Pharmaceuticals Price History and analyze Rhythm Pharmaceuticals Performance. Rhythm Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rhythm Pharmaceuticals market risk premium is the additional return an investor will receive from holding Rhythm Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rhythm Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rhythm Pharmaceuticals' performance over market.| α | -0.05 | β | 0.93 |
Rhythm Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rhythm Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Rhythm Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rhythm Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Rhythm Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rhythm Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rhythm Pharmaceuticals stock market price indicators, traders can identify Rhythm Pharmaceuticals position entry and exit signals to maximize returns.
Rhythm Pharmaceuticals Return and Market Media
The median price of Rhythm Pharmaceuticals for the period between Fri, Nov 14, 2025 and Thu, Feb 12, 2026 is 104.77 with a coefficient of variation of 4.62. The daily time series for the period is distributed with a sample standard deviation of 4.86, arithmetic mean of 105.17, and mean deviation of 3.96. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Pamela Cramer of 10546 shares of Rhythm Pharmaceuticals at 6.8 subject to Rule 16b-3 | 11/18/2025 |
2 | Disposition of 3350 shares by Pamela Cramer of Rhythm Pharmaceuticals at 27.35 subject to Rule 16b-3 | 11/20/2025 |
3 | Rhythm Pharmaceuticals Hits New 12-Month High Heres Why | 12/11/2025 |
4 | Acquisition by Pamela Cramer of 3350 shares of Rhythm Pharmaceuticals at 27.35 subject to Rule 16b-3 | 12/19/2025 |
5 | Rhythm Pharmaceuticals, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts - MarketBeat | 12/29/2025 |
6 | CEO Moves Why Rhythm Pharmaceuticals Inc. stock fits value portfolios - 2025 Biggest Moves Advanced Swing Trade Entry Alerts - ulpravda.ru | 01/08/2026 |
7 | Rhythm Pharmaceuticals stock price target raised to 125 from 123 at H.C. Wainwright - Investing.com | 01/20/2026 |
8 | Equities Analysts Offer Predictions for RYTM FY2025 Earnings | 01/22/2026 |
9 | Acquisition by Tetrault Lynn A. of 4712 shares of Rhythm Pharmaceuticals subject to Rule 16b-3 | 01/27/2026 |
10 | Disposition of 2343 shares by Pamela Cramer of Rhythm Pharmaceuticals subject to Rule 16b-3 | 01/30/2026 |
11 | This High-Flying Growth Stock Is Hiding in Plain Sight - The Motley Fool | 02/02/2026 |
12 | Disposition of 9163 shares by Jennifer Lee of Rhythm Pharmaceuticals subject to Rule 16b-3 | 02/03/2026 |
13 | Disposition of 747 shares by Smith Hunter C of Rhythm Pharmaceuticals at 107.6654 subject to Rule 16b-3 | 02/04/2026 |
14 | Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit | 02/05/2026 |
15 | Insider Sell Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc - GuruFocus | 02/06/2026 |
16 | Analyzing Rhythm Pharmaceuticals Belite Bio | 02/11/2026 |
About Rhythm Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rhythm or other stocks. Alpha measures the amount that position in Rhythm Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Dividend Yield | 0.001046 | 9.3E-4 | Price To Sales Ratio | 30.18 | 28.67 |
Rhythm Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Rhythm Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rhythm Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rhythm Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rhythm Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Rhythm Pharmaceuticals' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rhythm Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Rhythm Pharmaceuticals Analysis, Rhythm Pharmaceuticals Valuation, Rhythm Pharmaceuticals Correlation, Rhythm Pharmaceuticals Hype Analysis, Rhythm Pharmaceuticals Volatility, Rhythm Pharmaceuticals Price History and analyze Rhythm Pharmaceuticals Performance. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Rhythm Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.